Articles from Atropos Health

Atropos Health, a pioneer in translating clinical real-world data into personalized real-world evidence (RWE) and insights, and xCures, a pioneer in AI-powered healthcare data retrieval, extraction and structuring, announced today a partnership to harness RWE-based insights to support patient care. Through this partnership, the companies will leverage AI, the Atropos Evidence™ Network, and the xCures Platform to develop and deploy rigorously validated prognostic and decision support tools to healthcare providers across the healthcare ecosystem.

Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence, today announced the deployment of AI models for patient identification of patients living with undiagnosed conditions. The AI models will be deployed to clinicians by members of the Atropos Evidence™ Network.

Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today announced it will collaborate with Merck as a premier platform to generate RWE, replicate studies and produce rapid insights and analytics on real-world data (RWD). Through this collaboration, Atropos Health will enable rapid cohort creation, advanced analytics and publication-grade studies in less than 48 hours.

Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence, today announced a strategic partnership to accelerate precision medicine and expand the Immunology Multimodal Network, advancing shared decision making for patients with rheumatoid arthritis (RA). This collaboration will leverage Scipher's unique data and intelligence derived from its PrismRA® precision medicine diagnostic and expand the Atropos Evidence™ Network , enhancing the immunology multimodal network on Atropos Health’s GENEVA OS™(Generative Evidence Acceleration Operating System).

Atropos Health, a leader in translating clinical data into high-quality, personalized, real-world evidence (RWE) for care, today announced the availability of AI model training on the Atropos Evidence Network, the largest federated healthcare data network with more than 300 million patient records. Atropos Evidence Network members can utilize certain de-identified real-world data (RWD) to train AI models and seamlessly deploy their technology via channel partner systems, including pharmaceutical companies and health systems.

Atropos Health, the leader in translating real-world clinical data into high-quality personalized real-world evidence for care, is proud to announce its inclusion on the Inc. 2024 Best in Business list in the AI and Data category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.

Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced the release of ChatRWD, after a successful beta program. The company previously published ChatRWD’s superior performance over other large language models (LLMs) when it comes to trust, quality, and accuracy (limited hallucinations).

Atropos Health today announced the availability of Data Quality ScoreCards to members of the Atropos Evidence™ Network, the largest federated healthcare data network with 300M+ patient records. By joining the Atropos Evidence Network, data contributors receive confidential, transparent, analytically driven feedback on their own data quality and strengths and access to the most advanced AI tools.

Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced the publication of “Answering Real-World Clinical Questions Using Large Language Model Based Systems” which clearly details ChatRWD’s superiority over other large language models (LLMs) when it comes to trust, quality, and accuracy (limited hallucinations). The paper comes on the heels of the successful beta launch in Q42023.

Atropos Health today announced the expansion of the Atropos Evidence Network to include two new partners, adding to the growing number of datasets and use cases for the Atropos Evidence Network including oncology and international. The company additionally announced a new customer - Translational Drug Development (TD2) - which will gain immediate access to clinical insights generated from Atropos Health’s new data contributors.

Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced a $33 million Series B on the heels of the adoption of its Generative AI platform (GENEVA OS™) by healthcare institutions, data platforms, research institutions, life sciences companies and more. The funding was led by Valtruis, with participation from new strategic investors including Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures.

Today, Atropos Health, a pioneer in translating real-world clinical data into personalized, real-world evidence and insights, published a whitepaper outlining how its Real World Data Score (RWDS) and Real World Fitness Score (RWFS) also referred to as “Fitness Quotient” or “FitQ,” solve for the two most significant gaps that currently exist for real-world evidence in healthcare—quantitative evaluation metrics for datasets and the ability to evaluate fitness-for-purpose assessments.

Atropos Health, a pioneer in translating real-world clinical data into personalized real-world evidence and insights, today announced that it has optimized Atropos Health’s GENEVA™ OS (Generative Evidence Acceleration Operating System) to now work with Google Cloud's healthcare offerings, including Google Cloud’s Healthcare Data Engine (HDE), leveraging HDE application programming interfaces and BigQuery. This powerful pairing enables customers to efficiently and securely convert data into valuable insights and evidence.

Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence and insights, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can so that patients don’t suffer while cures hide on the pharmacy shelf. The collaboration allows Every Cure to leverage GENEVA OS™ and data from the Atropos Evidence™ Network to confirm and enhance findings from their AI driven data platform in the real world. By doing this, it offers key real world signals and generation of AI model features to emulate the effect of therapies in real world populations. This rapid, high quality evidence generation dramatically accelerates the potential of yielding new uses for existing drugs and can accelerate clinical development by providing a real-world signal of patient response.

Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence and insights, today announced that Arcadia (arcadia.io), a leading data platform for healthcare, joined the Atropos Evidence™ Network. The partnership provides Arcadia’s provider customers with access to the Atropos Health portfolio of evidence generating applications to support whole person care and value-based performance. Arcadia customers that subscribe to Atropos Health can help accelerate appropriate clinical decision making to drive high-value, low-cost care for patients based on their unique physiology. In addition, Atropos Health’s Life Sciences users can conduct real-world evidence (RWE) studies leveraging Arcadia’s longitudinal research dataset as part of the Atropos Evidence Network.

Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence and insights, today announced a strategic partnership with SEQSTER, the pioneer in patient-centric healthcare data technology. Healthcare and life science organizations leveraging the Atropos Health Evidence™ Network can establish turnkey patient registries to accelerate evidence generation. This process, previously costing millions and requiring up to a year, marks a significant leap forward in speed-to-insight for many underrepresented populations served by registry based research.

CB Insights today named Atropos Health to its fifth-annual Digital Health 50 (formerly the Digital Health 150), showcasing the 50 most promising private digital health companies of 2023.

Atropos Health, the pioneer in translating data into personalized real-world insights across healthcare, today announced the formation of its Life Sciences Advisory Board consisting of executives from the world’s preeminent pharmaceutical companies including Moderna, Novartis, and more. This announcement comes on the heels of Atropos Health launching Geneva OS™(Generative Evidence Acceleration Operating System) and ChatRWD™ (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation.

Atropos Health, leader in evidence generation for healthcare, today announced the launch of the Geneva OS™(Generative Evidence Acceleration Operating System) and the ChatRWD™ (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation. The new offering will enable non technical users to generate publication grade Observational Research studies leveraging deidentified patient level real world data from the Atropos Evidence Network in a matter of minutes, saving organizations valuable time, money, and staffing resources.

Atropos Health, a pioneer in evidence-based healthcare known for its Green Button Clinical Informatics Consult Service, today announced an agreement with Janssen Research & Development, LLC (Janssen), a Johnson & Johnson company, to help accelerate clinical development with real-world data analysis.

Atropos Health, a pioneer in evidence-based healthcare known for its Green Button Clinical Informatics Consult Service, today announced that it has completed a strategic financing from Presidio Ventures, the venture arm of Sumitomo Corporation Venture Group, Samsung Next, a venture arm of Samsung Electronics, Gaingels, Audere Capital, and others. The funding enables Atropos Health to accelerate commercial and development opportunities outside the U.S., using its proprietary technology and approach. Initial focus centers on key customers in Japan and Brazil.